SENS Senseonics
- 0.5049
- -0.0132-2.55%
- 0.5102
- +0.0053+1.05%
Senseonics News
Senseonics Holdings, Inc. to Participate in Upcoming Conferences
Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today
Senseonics Holdings, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 13, 2024 at 4:30 P.M. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos
Express News | Senseonics Announces Eversense CGM System Received ICGM Designation By FDA
Eversense CGM System Receives ICGM Designation by the US FDA
The first fully implantable continuous glucose monitors can now be integrated with insulin pumps as part of an automated insulin delivery system Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company
Senseonics Board Shift: Schumm Out, Hansen In Until 2025
Even Though Sensirion Holding (VTX:SENS) Has Lost CHF67m Market Cap in Last 7 Days, Shareholders Are Still up 48% Over 5 Years
While Sensirion Holding AG (VTX:SENS) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 23% in the last quarter.
SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS
HC Wainwright & Co. Reiterates Buy on Senseonics Holdings, Maintains $2 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Senseonics Holdings with a Buy and maintains $2 price target.
Senseonics Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/11/2024 223.89% HC Wainwright & Co. → $2 Reiterates Buy → Buy 11/14/2023 223.89% HC Wainwright & Co. →
Analysts Offer Insights on Healthcare Companies: Trevena (TRVN), MoonLake Immunotherapeutics (MLTX) and Senseonics Holdings (SENS)
Express News | Senseonics Holdings Announces Data From Eversense Post Approval Study To Be Presented At 17th International Conference On Advanced Technologies And Treatments for Diabetes
Senseonics Holdings, Inc. Announces Data From the Eversense Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today
Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference
Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today
Senseonics Holdings, Inc. (AMEX:SENS) Q4 2023 Earnings Call Transcript
Earnings Call: Senseonics Reports Robust Growth, Aims for 365-day CGM Launch
Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS), Azitra Inc (AZTR) and Dexcom (DXCM)
Senseonics Slips Amid Concerns Over Demand for Eversense
Senseonics Holdings (SENS) Receives a Hold From BTIG
Hewlett Packard Enterprise Posts Mixed Q1 Results, Joins Fisker, Plug Power And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures trading lower by around 100 points on Friday.
Earnings Call Summary | Senseonics(SENS.US) Q4 2023 Earnings Conference
The following is a summary of the Senseonics Holdings, Inc. (SENS) Q4 2023 Earnings Call Transcript:Financial Performance:Senseonics reported Q4 2023 revenue of $8 million, with annual revenue of $22.
Analysis
Price Target
No Data
